157 related articles for article (PubMed ID: 8774570)
1. Risk factors for ifosfamide nephrotoxicity in children.
Skinner R; Pearson AD; English MW; Price L; Wyllie RA; Coulthard MG; Craft AW
Lancet; 1996 Aug; 348(9027):578-80. PubMed ID: 8774570
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
3. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
Rossi R; Gödde A; Kleinebrand A; Riepenhausen M; Boos J; Ritter J; Jürgens H
J Clin Oncol; 1994 Jan; 12(1):159-65. PubMed ID: 8270973
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity after ifosfamide.
Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
[TBL] [Abstract][Full Text] [Related]
5. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
6. Chronic ifosfamide nephrotoxicity in children.
Skinner R
Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Skinner R; Cotterill SJ; Stevens MC
Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
[TBL] [Abstract][Full Text] [Related]
8. Mesna excretion and ifosfamide nephrotoxicity in children.
Goren MP; Pratt CB; Meyer WH; Wright RK; Dodge RK; Viar MJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7153-7. PubMed ID: 2510931
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide nephrotoxicity in pediatric cancer patients.
Lee BS; Lee JH; Kang HG; Hahn H; Lee JH; Shin HY; Ha IS; Cheong HI; Ahn HS; Choi Y
Pediatr Nephrol; 2001 Oct; 16(10):796-9. PubMed ID: 11605785
[TBL] [Abstract][Full Text] [Related]
10. Toxicity of high-dose ifosfamide in children.
Davies SM; Pearson AD; Craft AW
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S8-10. PubMed ID: 2503259
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, mesna, and nephrotoxicity in children.
Skinner R; Sharkey IM; Pearson AD; Craft AW
J Clin Oncol; 1993 Jan; 11(1):173-90. PubMed ID: 8418231
[TBL] [Abstract][Full Text] [Related]
12. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
[TBL] [Abstract][Full Text] [Related]
13. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors.
Loebstein R; Koren G
Pediatrics; 1998 Jun; 101(6):E8. PubMed ID: 9606250
[TBL] [Abstract][Full Text] [Related]
15. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
16. Growth impairment after ifosfamide-induced nephrotoxicity in children.
Stöhr W; Patzer L; Paulides M; Kremers A; Beck JD; Langer T; Rossi R
Pediatr Blood Cancer; 2007 May; 48(5):571-6. PubMed ID: 16755549
[TBL] [Abstract][Full Text] [Related]
17. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
18. Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
Fujieda M; Matsunaga A; Hayashi A; Tauchi H; Chayama K; Sekine T
J Toxicol Sci; 2009; 34 Suppl 2():SP251-7. PubMed ID: 19571477
[TBL] [Abstract][Full Text] [Related]
19. Renal function in children and adolescents following 72 g/m2 of ifosfamide.
Arndt C; Morgenstern B; Wilson D; Liedtke R; Miser J
Cancer Chemother Pharmacol; 1994; 34(5):431-3. PubMed ID: 8070011
[TBL] [Abstract][Full Text] [Related]
20. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Skinner R
Pediatr Nephrol; 2018 Feb; 33(2):215-225. PubMed ID: 28434047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
